The vast majority of HR+ BCs are human epidermal growth factor receptor 2 (HER2)-negative (HER2-), with less than 10% of HR+ tumours being HER2-positive (HER2+) in addition to overexpressing ER and/or PR [5,6]. This evidence concerns the gene ERBB2 and neoplasm.